Patient screening to begin this month DURHAM, NC, April 20, 2026 – Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power … The post Atsena Therapeutics Receives Data Monitoring Committee Recommendation to Proceed with Pivotal Part C Cohort of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis appeared first on Atsena Therapeutics .